We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

R-BIOPHARM

R-Biopharm AG is a biotechnology company that offers innovative products for numerous applications in the area of cli... read more Featured Products: More products

Download Mobile App




Rapid Immunochromatographic Tests Evaluated for Novel Norovirus

By LabMedica International staff writers
Posted on 08 Feb 2016
A worldwide spread is conceivable as a novel Norovirus emerged in Asia in the winter of 2014/15 and Norovirus diagnostic assays need to be evaluated to investigate if they adequately detect this emerging genotype.

Seven commercially available Norovirus immunochromatographic (IC) tests are available in Europe and all have the capacity to detect strains of genogroup GII.17 in stool, but sensitivities vary and partly depend on the viral load in the samples.

Virologists at the University Hospital of Dijon (Dijon, France) used 10 samples that had been collected from patients affected by five different gastroenteritis outbreaks. More...
One outbreak was related to oyster consumption, while the four others were caused by person-to-person transmission. Three of the four latter outbreaks had occurred in nursing homes and the fourth in a hospital. All 10 samples had been previously shown to be GII.17 Norovirus-positive by sequencing of the ribonucleic acid (RNA)-dependent RNA polymerase (RdRp) region and the N-terminal/shell (N/S) region.

All seven commercial IC tests were performed according to the manufacturers’ instructions. Due to limited amounts of samples, one assay per test was done, except when the results were negative, in which case they were controlled by a second assay when possible. The virus copy numbers were quantified by real-time reverse transcription-polymerase chain reaction (RT-PCR) on the same day. Measurements of the virus titers in each sample allowed to demonstrate that a positive result could be obtained with most of the IC tests (five in seven) if the samples presented a minimal load of 4.88 × 108 virus copies/g of stool. The lowest viral load detected by an IC test was 6.54 × 106 copies/g of stool and this gave a weak positive signal with the RidaQuick Norovirus test (R-Biopharm AG, Darmstadt, Germany). Three samples in the study, all of which had relatively high viral loads of greater than 1.34 × 109 copies/g of stool nevertheless gave negative results with some of the tests.

The authors concluded that the seven IC tests evaluated were able to detect GII.17 with various sensitivities due to virus titers, and possibly antigenic differences and kit design. Therefore some IC tests may need to be optimized for the detection of Norovirus genogroup GII.17. The study was published on January 28, 2016, in the journal Eurosurveillance.

Related Links:

University Hospital of Dijon
R-Biopharm AG 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Automated Immunoassay Analyzer
SuperFlex™
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.